AU2006227528B2 - Use of ADNF polypeptides for treating peripheral neurotoxicity - Google Patents

Use of ADNF polypeptides for treating peripheral neurotoxicity Download PDF

Info

Publication number
AU2006227528B2
AU2006227528B2 AU2006227528A AU2006227528A AU2006227528B2 AU 2006227528 B2 AU2006227528 B2 AU 2006227528B2 AU 2006227528 A AU2006227528 A AU 2006227528A AU 2006227528 A AU2006227528 A AU 2006227528A AU 2006227528 B2 AU2006227528 B2 AU 2006227528B2
Authority
AU
Australia
Prior art keywords
ser
ala
leu
pro
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006227528A
Other languages
English (en)
Other versions
AU2006227528A1 (en
Inventor
Illana Gozes
James Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allon Therapeutics Inc
Ramot at Tel Aviv University Ltd
Original Assignee
Allon Therapeutics Inc
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allon Therapeutics Inc, Ramot at Tel Aviv University Ltd filed Critical Allon Therapeutics Inc
Publication of AU2006227528A1 publication Critical patent/AU2006227528A1/en
Application granted granted Critical
Publication of AU2006227528B2 publication Critical patent/AU2006227528B2/en
Priority to AU2012200874A priority Critical patent/AU2012200874A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
AU2006227528A 2005-03-23 2006-03-23 Use of ADNF polypeptides for treating peripheral neurotoxicity Ceased AU2006227528B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012200874A AU2012200874A1 (en) 2005-03-23 2012-02-15 Use of ADNF polypeptides for treating peripheral neurotoxicity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66490805P 2005-03-23 2005-03-23
US60/664,908 2005-03-23
PCT/CA2006/000438 WO2006099739A1 (en) 2005-03-23 2006-03-23 Use of adnf polypeptides for treating peripheral neurotoxicity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012200874A Division AU2012200874A1 (en) 2005-03-23 2012-02-15 Use of ADNF polypeptides for treating peripheral neurotoxicity

Publications (2)

Publication Number Publication Date
AU2006227528A1 AU2006227528A1 (en) 2006-09-28
AU2006227528B2 true AU2006227528B2 (en) 2011-05-26

Family

ID=37023352

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006227528A Ceased AU2006227528B2 (en) 2005-03-23 2006-03-23 Use of ADNF polypeptides for treating peripheral neurotoxicity

Country Status (6)

Country Link
US (2) US7452867B2 (cg-RX-API-DMAC7.html)
EP (1) EP1885389A4 (cg-RX-API-DMAC7.html)
JP (1) JP5174653B2 (cg-RX-API-DMAC7.html)
AU (1) AU2006227528B2 (cg-RX-API-DMAC7.html)
CA (1) CA2602893A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006099739A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613740B1 (en) * 1997-02-07 2003-09-02 Ramot University Authority For Applied Research And Industrial Development Ltd. Activity dependent neurotrophic factor III (ADNF III)
US6933277B2 (en) 1999-03-12 2005-08-23 The United States Of America As Represented By The Department Of Health And Human Services Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides
US7384908B1 (en) * 1999-08-18 2008-06-10 National Institute Of Health Orally active peptides that prevent cell damage and death
US7427590B2 (en) * 2001-09-12 2008-09-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Neurothrophic components of the ADNF I complex
US7960334B2 (en) * 2003-03-12 2011-06-14 Ramot At Tel-Aviv University Ltd. Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia
JP5174653B2 (ja) * 2005-03-23 2013-04-03 ラモト アト テルーアビブ ユニバーシティー リミテッド 末梢神経毒症状を処置するためのadnfポリペプチドの使用
WO2007096859A2 (en) * 2006-02-24 2007-08-30 Ramot At Tel-Aviv University Ltd. Protection of the retina against laser injury by adnf peptides such as nap and sal
WO2008084483A1 (en) 2007-01-11 2008-07-17 Ramot At Tel Aviv University Ltd. Novel therapeutics based on tau/microtubule dynamics
CN101848934A (zh) * 2007-08-24 2010-09-29 以色列特拉维夫大学拉莫特技术转移公司 使用nap样和sal样肽模拟物的神经保护
US7998928B2 (en) * 2007-09-14 2011-08-16 The Regents Of The University Of California Method of treatment of type-1 diabetes with a humanin analogue
WO2010033762A1 (en) * 2008-09-18 2010-03-25 Youssef Sari Colivelin as a neuroprotective factor
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
EP2381955A4 (en) * 2008-12-30 2013-01-16 Univ Ramot COMBINATION THERAPIES WITH NAP
EP2467397A1 (en) 2009-08-17 2012-06-27 Ramot at Tel-Aviv University Ltd. Nap alpha-aminoisobutyric acid analog with neuroprotective activity
WO2011032175A1 (en) 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
EP2521919B1 (en) 2010-01-06 2015-03-04 Ramot at Tel Aviv University, Ltd. Method for diagnosing and monitoring schizophrenia and tauopathies
FR2957077B1 (fr) * 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
WO2017130190A1 (en) * 2016-01-28 2017-08-03 Ramot At Tel-Aviv University Ltd. Novel formulation of neuroprotective peptides
EP3245944A1 (en) * 2016-05-20 2017-11-22 Institut Pasteur Olfactory means for the diagnosis of neurological complications of nervous system infection
US11571396B2 (en) 2019-03-23 2023-02-07 Sandra Sermone Ketamine for treatment of ADNP syndrome and sensory processing deficits
EP3979995A4 (en) 2019-06-04 2023-07-26 ADNP Kids Research Foundation Ketamine and ketamine/nap for treatment of adnp syndrome and related neurological conditions
WO2022003673A1 (en) 2020-06-30 2022-01-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Humanin analogs and uses thereof
US20250032580A1 (en) * 2021-03-25 2025-01-30 Ramot At Tel-Aviv University Ltd. Use of adnf polypeptides in therapy
CA3213068A1 (en) 2021-03-25 2022-09-29 Ramot At Tel-Aviv University Ltd. Compositions and articles comprising an adnf polypeptide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027875A2 (en) * 1998-11-06 2000-05-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Activity dependent neurotrophic factor iii (adnf iii)
WO2001012654A2 (en) * 1999-08-18 2001-02-22 Ramot University Authority For Applied Research & Industrial Development Ltd. Orally active peptides that prevent cell damage and death
US20030166544A1 (en) * 2000-09-07 2003-09-04 Clark Abbot F. Use of ADNP for the treatment of glaucomatous optic neuropathy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740497A (en) 1971-06-29 1973-06-19 G Daniell Artificial line bridge subscriber dial long line equipment tester
US4587046A (en) 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
US5198420A (en) * 1989-10-02 1993-03-30 The General Hospital Corporation Use of mullerian inhibiting substance and its agonists and antagonists in the treatment of respiratory distress syndrome
US6174862B1 (en) 1991-04-22 2001-01-16 Ramot University Authority For Applied Research And Industrial Development, Ltd. Neurotrophic peptides of activity dependent neurotrophic factor
US5767240A (en) 1991-04-22 1998-06-16 The United States Of America As Represented By The Department Of Health And Human Services Activity-dependent neurotrophic factor
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
EP2172478A3 (en) * 1997-02-07 2010-07-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Activity-dependent neurotrophic factor III (ADNF III)
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6933277B2 (en) 1999-03-12 2005-08-23 The United States Of America As Represented By The Department Of Health And Human Services Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US6649411B2 (en) * 1999-07-30 2003-11-18 The United States Of America As Represented By The Department Of Health And Human Services Methods of inhibiting cancer cells with ADNF III antisense oligonucleotides
US7384908B1 (en) * 1999-08-18 2008-06-10 National Institute Of Health Orally active peptides that prevent cell damage and death
US7427598B2 (en) * 2000-05-31 2008-09-23 The United States Of Americas As Represented By The Secretary Of The Department Of Health And Human Services Post-natal administration of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory
US7427590B2 (en) * 2001-09-12 2008-09-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Neurothrophic components of the ADNF I complex
US7960334B2 (en) * 2003-03-12 2011-06-14 Ramot At Tel-Aviv University Ltd. Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia
JP5174653B2 (ja) * 2005-03-23 2013-04-03 ラモト アト テルーアビブ ユニバーシティー リミテッド 末梢神経毒症状を処置するためのadnfポリペプチドの使用
WO2007096859A2 (en) * 2006-02-24 2007-08-30 Ramot At Tel-Aviv University Ltd. Protection of the retina against laser injury by adnf peptides such as nap and sal
CN101848934A (zh) * 2007-08-24 2010-09-29 以色列特拉维夫大学拉莫特技术转移公司 使用nap样和sal样肽模拟物的神经保护

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027875A2 (en) * 1998-11-06 2000-05-18 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Activity dependent neurotrophic factor iii (adnf iii)
WO2001012654A2 (en) * 1999-08-18 2001-02-22 Ramot University Authority For Applied Research & Industrial Development Ltd. Orally active peptides that prevent cell damage and death
US20030166544A1 (en) * 2000-09-07 2003-09-04 Clark Abbot F. Use of ADNP for the treatment of glaucomatous optic neuropathy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chiba, T et al., J. Neurosci. Res., 2004, Vol.78, No.4, pages 542-552 *

Also Published As

Publication number Publication date
JP5174653B2 (ja) 2013-04-03
CA2602893A1 (en) 2006-09-28
JP2008535805A (ja) 2008-09-04
US8143221B2 (en) 2012-03-27
WO2006099739A1 (en) 2006-09-28
EP1885389A1 (en) 2008-02-13
US20060247168A1 (en) 2006-11-02
EP1885389A4 (en) 2012-04-04
US7452867B2 (en) 2008-11-18
AU2006227528A1 (en) 2006-09-28
US20090137469A1 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
US8143221B2 (en) Use of ADNF polypeptides for treating peripheral neurotoxicity
US12503501B2 (en) Treatment of central nervous system disorders by intranasal administration of immunoglobulin G
US20110053859A1 (en) Methods to reduce the effects of sleep deprivation
EP0541686A1 (en) Tachykinin agonists for treatment of alzheimer's disease
KR20240025721A (ko) 노화와 연관된 질환을 치료하기 위한 방법 및 조성물
JP2012514011A (ja) Napを用いる併用治療の方法
JP2010536801A (ja) Nap様ペプチド擬似体およびsal様ペプチド擬似体を用いた神経保護法
WO2003047514A2 (en) Reducing myelin-mediated inhibition of axon regeneration
EP2212349B1 (en) Synthetic analogues of neural regeneration peptides
EP3019242B1 (en) Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist
WO2013082045A1 (en) Netrin loop peptide mimetics and uses thereof
MX2009001591A (es) Metodo para seleccionar compuestos con propiedades antiamiloides.
US7572450B2 (en) Composition for preventing cell death and/or tissue necrosis resulting from contact with neural thread proteins
JP7757322B2 (ja) Fgfr3関連の認知欠損の処置のための方法及び医薬組成物
EP4103223A2 (en) Platelet factors and cognitive improvement
AU2012200874A1 (en) Use of ADNF polypeptides for treating peripheral neurotoxicity
CN120882734A (zh) 用于治疗神经紊乱的肽
JP2020530846A (ja) 方法
WO2012015910A2 (en) Use of adnf polypeptides for treating neurodegenerative diseases
US20130065825A1 (en) Compositions and Methods for Delaying Senescence or Cell Death in Neurons
EP1541166B1 (en) Preventing cell death using segments of neural thread proteins
KR20240035381A (ko) 시냅스 전달을 강화하기 위한 sco-스폰딘-유래 폴리펩타이드
WO2025227011A1 (en) Immunotherapy compositions and methods for treatment of tauopathy, neuroinflammation, and synaptic loss
AU2002302239B2 (en) Method of preventing cell death using segments of neural thread proteins
WO1999051736A1 (en) Neuron regulatory factor comprising a small peptide for promoting neuron survival

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired